Inhibrx Biosciences, Inc. (INBX)
123.41
-0.52
(-0.42%)
USD |
NASDAQ |
Aug 28, 16:00
123.34
-0.07
(-0.06%)
After-Hours: 20:00
Inhibrx Biosciences Debt to Equity Ratio : -3.428 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.428 |
| March 31, 2026 | -8.600 |
| December 31, 2025 | 13.39 |
| September 30, 2025 | 2.903 |
| June 30, 2025 | 1.558 |
| March 31, 2025 | 1.128 |
| Date | Value |
|---|---|
| December 31, 2024 | 0.0602 |
| September 30, 2024 | 0.0103 |
| June 30, 2024 | 0.0099 |
| March 31, 2024 | 18.23 |
| December 31, 2023 | 4.830 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| AnaptysBio, Inc. | 21.76 |
| 4D Molecular Therapeutics, Inc. | 0.0962 |
| Design Therapeutics, Inc. | 0.0132 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 154.22M |
| Total Liabilities (Quarterly) | 207.20M |
| Shareholders Equity (Quarterly) | -52.98M |
| Current Ratio | 5.067 |
| Net Debt Paydown Yield | -1.08% |